Shilpa Venkatachalam

TL;DR: In this article, the authors developed clinically relevant population, intervention, comparator, and outcomes (PICO) questions to develop updated guidelines for the pharmacologic management of rheumatoid arthritis.

TL;DR: In the early months of the COVID-19 pandemic, patients with RA, PsA, AS, and SLE frequently avoided office visits and laboratory testing and were associated with SES, office visits, and telehealth availability, highlighting the need for adequate healthcare access and attention to vulnerable populations during the pandemic.

TL;DR: Key issues, processes, and outcomes related to development of a patient registry for rheumatology research using a digital platform where patients track useful data about their condition for their own use while contributing to research are described.

TL;DR: Patient-reported outcomes (PROs) are increasingly used to track symptoms and to assess disease activity, quality of life, and treatment effectiveness as discussed by the authors, and it is important to understand which PROs patients with rheumatic and musculoskeletal disease consider most important to track for disease management.

TL;DR: During the diagnosis process, men with AS tended to receive quicker AS diagnosis compared with women, and commonly reported initial diagnoses among respondents with longer time to AS diagnosis included back problems and psychosomatic disorders.